KR20230028710A - Composition for preventing, improving or treating of muscular disease containing Angelica dahurica extract - Google Patents

Abstract

The present invention relates to a composition for preventing, improving or treating muscular diseases containing angelica dahurica extract as an active ingredient; a composition for strengthening muscle; a composition for promoting muscle differentiation; and a composition for enhancing athletic performance. The composition can be usefully used for preventing, improving, or treating muscle diseases by promoting muscle differentiation and inhibiting muscle atrophy factors and muscle differentiation inhibitors.

Description

Composition for preventing, improving or treating muscular disease containing Angelica dahurica extract}

The present invention relates to a composition for the prevention, improvement or treatment of muscle diseases, comprising an extract of copperhead as an active ingredient; composition for muscle strengthening; a composition for promoting muscle differentiation; And it relates to a composition for enhancing athletic performance.

Muscle is a tissue with the largest composition in the human body, and it is essential to secure an appropriate amount of muscle in order to maintain the functional capacity of the human body and prevent metabolic diseases. Muscle size is regulated by intracellular signaling pathways that induce anabolism or catabolism in muscle. When more signal transduction reactions that induce muscle protein synthesis than degradation occur, muscle protein synthesis increases, resulting in hypertrophy, which increases muscle size, or increases in the number of muscle fibers (hyperplasia) (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011).

As the body ages, redistribution of body fat and body proteins occurs as a result of changes in composition. At the age of about 50, the synthesis rate of protein in muscle cells slows down compared to the rate of degradation, and muscles begin to degenerate rapidly, and are exposed to muscle loss diseases. can

Sarcopenia, which is one of muscle loss diseases, refers to a state in which about 13 to 24% of one's usual body mass is reduced, and represents a decrease in protein content, fiber diameter, muscle strength production, and fatigue resistance. Sarcopenia is caused by a variety of causes, including sepsis, cancer, renal failure, excess glucocorticoids, denervation, muscle disuse, and the aging process. Mainly, the gradual decrease in the quantity and quality of skeletal muscle as aging progresses and weight loss including fat and body fat components due to inadequate dietary energy intake can be cited as causes, and it is often caused by aging and is closely related to age. .

Sarcopenia results from an imbalance between protein synthesis and breakdown. If you have sarcopenia, the amount of action is significantly reduced, which not only harms mental health, but also reduces satisfaction with life, and easily gets injured even in easy daily life and leads to serious serious injuries.

In addition, excessive exercise causes muscle fatigue and damage and reduces exercise capacity. Muscle injuries include contusion (bruise), laceration, ischemia, strain, and severe damage to skeletal muscle. Not only does this damage cause great pain, but it can also make it impossible for the injured person to continue to exercise, work, or even perform normal daily activities. With severe injuries to skeletal muscle, strains are the most common, and muscle strain injuries are characterized by destruction of muscle-tendon units. Disruption of these muscle-tendon units can occur anywhere in the muscle. Strain accounts for more than 30% of all injuries treated professionally or by sports medicine professionals.

Treatments that can reduce muscle damage or speed up muscle tissue recovery have the potential to speed recovery of muscle power generation after exercise. It may also aid in muscle recovery after an illness.

However, with the recent increase in interest in appearance and diet, rapid weight loss may cause sarcopenia regardless of age, and intense exercise may damage muscles. Therefore, studies and efforts are being focused on treating muscle loss caused by general muscle loss diseases or increasing muscles, and research on the treatment of muscle loss diseases and muscle strengthening is still required.

An object of the present invention is to provide a food composition for the prevention or improvement of muscle diseases, comprising a copper rod extract as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of muscle diseases comprising a copper rod extract as an active ingredient.

Another object of the present invention is to provide a composition for strengthening muscles containing copper rod extract as an active ingredient.

Another object of the present invention is to provide a composition for promoting muscle differentiation comprising copper rod extract as an active ingredient.

Another object of the present invention is to provide a composition for enhancing exercise capacity comprising copper bamboo extract as an active ingredient.

In order to achieve the above object, the present invention provides a food composition for the prevention or improvement of muscle disease containing copper rod extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of muscle diseases, comprising a copper rod extract as an active ingredient.

In addition, the present invention provides a composition for strengthening muscles containing copper rod extract as an active ingredient.

In addition, the present invention provides a composition for promoting muscle differentiation comprising copper bamboo extract as an active ingredient.

In addition, the present invention provides a composition for enhancing exercise capacity containing copper rod extract as an active ingredient.

The composition according to the present invention has the effect of enhancing or restoring muscle differentiation to strengthen muscles, reducing muscle atrophy to suppress muscle loss, and enhancing or improving exercise performance, which is useful in preventing, improving or treating muscle diseases. can be useful

Figure 1 is the result of measuring the cell viability according to the treatment of copper rod extract.
FIG. 2 shows the result of immunostaining for myosin heavy chain (MHC) after treating the myoblasts derived from mice derived from differentiation with copper rod extract; and (b) the result of calculating the convergence index.
Figure 3 is the result of confirming the mRNA expression levels of Atrogin-1, MuRF-1 (Muscle RING-finger protein-1) and Myostatin through qPCR after treating the copper rod extract to the differentiated mouse-derived myoblasts.
Figure 4 is a result of measuring grip strength after feeding copper rod extract to a mouse animal model.

Hereinafter, the present invention will be described in detail.

The present invention provides a food composition for preventing or improving muscle diseases comprising an extract of Angelica dahurica as an active ingredient.

The term of the present invention, "Kuritdae" is a perennial plant belonging to the umbel family, distributed in Northeast Asia, and mainly grows at the edges of mountains and valleys. The height is about 1~1.5m, and many beard roots sprout on the fat rhizome. The leaves are divided into several branches, oval in shape, and 5 to 10 cm long. White flowers bloom from June to August, and elliptical fruits bear fruit around October. In oriental medicine, the root is called baekji.

The extract according to the present invention may be obtained by extraction and separation from nature using an extraction and separation method known in the art, and the "extract" defined in the present invention is extracted from passionflower using an appropriate solvent. And, for example, it includes all of the crude extract, polar solvent-soluble extract, or non-polar solvent-soluble extract of copper stem.

Any suitable solvent for extracting the extract from the copper rod may be used as long as it is a pharmaceutically acceptable organic solvent, and water or an organic solvent may be used, but is not limited thereto. For example, purified water, methanol ( Alcohols having 1 to 4 carbon atoms including methanol, ethanol, propanol, isopropanol, butanol, etc., acetone, ether, benzene, chloroform ( chloroform), ethyl acetate, methylene chloride, hexane, and cyclohexane, etc. may be used alone or in combination.

As an extraction method, any one of methods such as hot water extraction, cold brew extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used. In addition, the desired extract may be additionally subjected to a conventional fractionation process or may be purified using a conventional purification method. There is no limitation on the preparation method of the copper rod extract of the present invention, and any known method may be used.

For example, the copper rod extract included in the composition of the present invention can be prepared in a powder state by an additional process such as vacuum distillation and freeze drying or spray drying of the primary extract extracted by the hot water extraction or solvent extraction method. In addition, a fraction further purified from the primary extract using various chromatography methods such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography. can also be obtained.

Therefore, in the present invention, copper bamboo extract is a concept that includes all extracts, fractions, and purified products obtained in each step of extraction, fractionation, or purification, and dilutions, concentrates, or dried products thereof.

In one embodiment of the present invention, the composition may inhibit the expression of Atrogin-1 and MuRF-1 (Muscle RING-finger protein-1) that cause muscle atrophy.

In one embodiment of the present invention, the composition may inhibit the expression of Myostatin, which inhibits muscle differentiation.

In one embodiment of the present invention, the extract may have a concentration of 0.1 μg / mL to 100 mg / mL, preferably a concentration of 0.1 μg / mL to 1 mg / mL, more preferably May be a concentration of 0.1 μg / mL to 100 μg / mL, more preferably a concentration of 0.1 μg / mL to 10 μg / mL, but is not limited thereto.

In one embodiment of the present invention, the extract may be included in 0.1 to 50 parts by weight based on 100 parts by weight of the composition, but is not limited thereto.

The muscle disease is a progressive disease characterized by loss of walking ability due to gradual decrease in muscle strength, weakening of respiratory muscle strength, weakening of heart function, etc. is a human disease In addition, muscle diseases can be divided into congenital diseases and acquired diseases, but are not limited to, atony, muscular atrophy, muscular dystrophy, muscular dystrophy, muscle stiffness, myasthenia, cachexia ( cachexia) or sarcopenia.

The food composition of the present invention may include all food in a conventional sense, and may be used interchangeably with terms known in the art, such as functional food and health functional food.

The term of the present invention, "functional food" refers to food manufactured and processed using raw materials or ingredients having useful functionalities for the human body according to the Act on Health Functional Foods No. 6727, and "functional" means It refers to intake for the purpose of obtaining useful effects for health purposes, such as regulating nutrients with respect to structure and function or physiological action.

The term of the present invention, "health functional food" refers to a food manufactured and processed by methods such as extracting, concentrating, refining, mixing, etc., using specific ingredients as raw materials or specific ingredients contained in food raw materials for the purpose of health supplementation. It refers to a food designed and processed to sufficiently exert biological control functions such as biological defense, regulation of biological rhythm, prevention and recovery of disease, etc. It can perform related functions, etc.

There are no restrictions on the types of foods in which the composition of the present invention can be used. In addition, the composition of the present invention may be prepared by mixing suitable other auxiliary ingredients that may be included in food and known additives according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and Vitamin complexes, etc., can be prepared by adding the extract and its fractions according to the present invention to juices, teas, jellies, juices, etc. prepared as main components.

In addition, foods that can be applied to the present invention include, for example, special nutritional foods (e.g., formula milk, infant, baby food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), health supplement food , seasonings (eg soy sauce, soybean paste, gochujang, mixed paste, etc.), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.) ), beverages (eg fruit, vegetable drinks, soy milk, fermented beverages, etc.), and natural seasonings (eg, ramen soup, etc.).

When the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweeteners, flavoring agents, or natural carbohydrates as additional components, like conventional beverages. In addition to the above, the health functional food composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, and glycerin. , alcohol, a carbonating agent used in carbonated beverages, and the like. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages and vegetable beverages.

In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of muscle diseases, comprising a copper rod extract as an active ingredient.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable" means that it exhibits non-toxic properties to cells or humans exposed to the composition. The carrier may be used without limitation as long as it is known in the art such as a buffer, a preservative, a pain reliever, a solubilizer, an isotonic agent, a stabilizer, a base, an excipient, a lubricant, and the like.

In addition, the pharmaceutical composition of the present invention is formulated in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively. can be used Furthermore, it may be used in the form of ointments, lotions, sprays, patches, creams, powders, suspensions, gels, or skin external preparations in the form of gels. Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient, for example, starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogeratin and the like may be used.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "administration" of the present invention means introducing a predetermined substance into a subject by an appropriate method, and the administration route of the composition may be administered through any general route as long as it can reach the target tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, intrarectal administration, but not limited thereto.

The term "individual" refers to all animals such as rats, mice, livestock, and the like, including humans. Preferably, it may be a mammal including a human.

The term "pharmaceutically effective amount" means an amount that is sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects, and the effective dose level is determined by the patient's gender, age, Factors including body weight, health condition, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration, and rate of excretion, duration of treatment, drugs used in combination or concurrently, and other medical disciplines. It can be easily determined by a person skilled in the art according to well-known factors. Administration may be administered once a day at the recommended dose, or may be administered in several divided doses.

In addition, the present invention provides a composition for strengthening muscles containing copper rod extract as an active ingredient.

As used herein, the term "muscle strengthening" refers to an effect of increasing muscle strength and/or size, and does not limit the type of muscle. Preferably, it exhibits an effect of increasing muscle mass and is characterized in that it exhibits an effect of inhibiting muscle loss.

The increase in muscle mass is to improve muscle performance, and can increase muscle mass through physical exercise and endurance improvement, and can increase muscle mass by administering a substance having a muscle increasing effect into the body. In addition, the muscle loss is characterized by a gradual loss of muscle mass, weakness and degeneration of muscles, especially skeletal or voluntary muscles and cardiac muscles, genetic factors, acquired factors. Aging may be the cause.

In addition, the present invention provides a composition for promoting muscle differentiation comprising copper bamboo extract as an active ingredient.

The term of the present invention, "muscle differentiation" is a process for forming muscles, and muscle differentiation first activates satellite cells (satellite cells), and the activated satellite cells are differentiated into myoblasts (Morgan, JE, et al, 2003). Differentiated myoblasts divide, and fusion of myoblasts occurs to develop into myotubes. These myotubes gather to form muscle fibers, which are bundled to form muscles. will form

In addition, the present invention provides a composition for enhancing exercise capacity containing copper rod extract as an active ingredient.

The term of the present invention, "exercise ability" refers to the ability to quickly, strongly, accurately, for a long time, and skillfully classify the body movements seen in daily life or sports into running, jumping, throwing, swimming, etc. As an indication of the degree to which one can perform, exercise performance is defined by factors such as muscular strength, agility, and endurance.

The term of the present invention, "exercise capacity enhancement" refers to improving or enhancing the exercise capacity. Preferably, the food composition exhibits an effect of increasing muscle strength, and is characterized in that it exhibits an effect of increasing muscle endurance. In addition, it may be to prevent or improve symptoms of, but not limited to, degenerative diseases, abnormal mitochondrial diseases, hypostamina, hypoacuity, lethargy, muscle wasting or depression.

Hereinafter, the present invention will be described in more detail through examples. These examples are intended to explain the present invention in more detail, and the scope of the present invention is not limited to these examples.

Example 1. Experimental method

1.1. statistical analysis

For all study results, one-way ANOVA was performed using GraphPad Prism 7 (GraphPad Software Inc., SanDiego, CA, USA), and statistical significance was verified by Boneferroni multiple comparison post test, *p<0.05, **p Marked as <0.01 and ***p<0.001.

1.2. Preparation of Copperhead Extract

The copper rod was dried with hot air and then pulverized to make a powder. Hot water extraction was performed for 2 hours using a 50% ethanol solvent in a volume 10 times the weight of the powder. The final product obtained by concentrating the extract under reduced pressure, freezing at -80 ° C and then freeze-drying was finely pulverized and used in the experiment.

Example 2. Cytotoxicity assay

An experiment was performed to confirm whether or not cytotoxicity was observed after treating the copper rod extract to mouse-derived myoblasts. Briefly, mouse-derived myoblasts, C2C12 cell line (CRL1772 ATCC, USA), were treated with copper rod extract at given concentrations (0.5, 1, 2.5, 5, and 10 μg/mL), and cell growth rates were analyzed after 24 hours.

As a result, it was confirmed that the copper rod extract did not exhibit cytotoxicity up to a concentration of 10 μg/mL (FIG. 1).

Example 3. Muscle differentiation (myogenesis) promoting or restoring effect by copper rod extract

The present inventors, in order to confirm whether the copper rod extract has an effect of enhancing muscle differentiation, treated mouse-derived myoblasts treated with dexamethasone with the copper rod extract, and then performed an experiment to confirm the degree of differentiation from myoblasts to myotubes. . Briefly, when C2C12 cell line (CRL1772 ATCC, USA), a mouse-derived myoblast, is grown to 100% confluence in a culture container, DMEM (Dulbecco's Modified Eagle) containing 2% HS (horse serum) and 1% PS (penicillin-streptomycin) Medium) medium, and differentiation was performed for a total of 4 days to form myotubes. On the 4th day of differentiation, after treatment with 1 and 2.5 μg/mL of dexamethasone and 5 μM dexamethasone for 24 hours, to confirm the degree of differentiation into myotubes, myosin heavy chain (MHC) ) immunostaining was performed.

Differentiated myotubes were fixed with 4% formaldehyde, permeabilized with 0.05% saponin, and blocked with 1% bovine serum albumin (BSA). Thereafter, a primary antibody and a secondary antibody for myosin heavy chain (MHC) were attached and stained, and nuclei were stained with DAPI. The fusion index (%) was calculated by the following formula: fusion index = (nuclei in myotubes / nuclei in all cells) × 100 (%).

As a result, in the dexamethasone-treated group (DEX), the MHC expression level decreased and the fusion index also significantly decreased, whereas in the dexamethasone-treated group (1 and 2.5 μg/mL), the MHC expression level was higher than that in the dexamethasone-treated group. significantly increased, and it was confirmed that the fusion index significantly increased (Figs. 2a and 2b).

As a result, it was confirmed that the copper rod extract has an effect of increasing root canal formation by restoring the degree of muscle differentiation reduced by dexamethasone.

Example 4. Effects of muscle atrophy or muscle differentiation regulator expression control by copper rod extract

In order to confirm that the copper rod extract changes the mRNA expression level of the muscle atrophy regulator and the muscle differentiation regulator, the present inventors treated the differentiated mouse-derived myoblasts with the rod rod extract, and then destroyed the muscle protein to cause muscle atrophy ( Atrogin-1 and MuRF-1 (Muscle RING-finger protein-1) known to cause atrophy); And an experiment was performed to confirm the mRNA expression level of Myostatin, known as a muscle differentiation inhibitor.

Briefly, the C2C12 cell line (CRL1772 ATCC, USA), a mouse-derived myoblast, was cultured in DMEM (Dulbecco's Modified Eagle Medium) medium containing 10% fetal bovine serum (FBS) and DMEM containing 2% HS (horse serum). The differentiation induction medium was treated for 4 days. After the induction of differentiation, 1 and 2.5 μg/mL of copper rodent extract and 5 μM of dexamethasone were treated.

After 24 hours, the cells were washed with PBS, and the cells were obtained, and total RNA was extracted using the NucleoSpin RNA Kit (Nacherey-Nagel, Duren, Germany) according to the manufacturer's instructions. Then, cDNA was synthesized using Synthesize cDNA for real-time PCR Kit (ReverTra Ace qPCR RT Master Mix, FSQ-201, TOYOBO), and then PCR was performed with SYBR Green MasterMix (TOYOBO Co. Ltd., Osaka, Japan). The mRNA expression levels of Atrogin-1, MuRF-1 and Myostatin were measured. Primer sequences specific to each gene are shown in Table 1 below.

Base sequence (5' -> 3') sequence number Atrogin-1 Sense GACTGGACTTCTCGACTGCC One Anti-sense TCAGGGATGTGAGCTGTGAC 2 MuRF-1 Sense GCTGGTGGAAAACATCATTGACAT 3 Anti-sense CATCGGGTGGCTGCCTTT 4 Myostatin Sense ACGCTACCACGGAAACAATC 5 Anti-sense GGAGTCTTGACGGGGTCTGAG 6 MyoG Sense GCAGGCTCAAGAAAGTGAATGA 7 Anti-sense TAGGCGCTCAATGTACTGGAT 8 MyoD Sense CGGGACATAGACTTGACAGGC 9 Anti-sense TCGAAACACGGGTCATCATAGA 10 18s RNA Sense GTAACCCGTTGAACCCCATT 11 Anti-sense CCATCCAATCGGTAGTAGCG 12

As a result, in the group treated with dexamethasone, the mRNA expression levels of Atrogin-1, MuRF-1 and Myostatin were significantly increased compared to the control group (DMSO) (FIG. 3). On the other hand, it was confirmed that the mRNA expression levels of Atrogin-1, MuRF-1, and Myostatin were significantly decreased in the group treated with copper rod extract (1 and 2.5 μg/mL) compared to the group treated with dexamethasone (FIG. 3).

From the above results, it was confirmed that the present invention has the effect of inhibiting the expression level of Atrogin-1 and MuRF-1, which cause muscle atrophy, and the expression level of Myostatin, which inhibits muscle differentiation, in the present invention.

Example 5. Effect of motor performance improvement by copper rod extract in mouse animal model

In order to confirm whether copper rod extract changes motor performance in mouse animal models, an experiment was performed to measure grip strength of mice. 8-week-old C57BL/6 male mice were used, and 0.1% (w/v) copper rodent extract was added to the AIN-93M Adult maintenance Rodent Diet (Research diet, D10012M) base and fed for 8 weeks. . Dexamethasone was intraperitoneally administered at 15 mg/kg/body weight 18 days before the mice were sacrificed. On the 17th day of intraperitoneal administration, the grip strength was measured 5 times with the forelimbs of the mouse, and then the average value was calculated. Skeletal muscle strength was expressed in g.

As a result, grip strength was reduced in mice fed dexamethasone (DEX) compared to the control group, whereas grip strength was significantly recovered or improved in mice fed copper rod extract (AD) compared to mice fed dexamethasone. It was confirmed that there is an effect (FIG. 4).

From the above results, in the present invention, it was confirmed that the copper rod extract has an effect of restoring, enhancing or improving exercise performance.

Claims (11)

A food composition for preventing or improving muscle diseases comprising an extract of Angelica dahurica as an active ingredient.
According to claim 1,
Wherein the extract is extracted with water, an organic solvent or a mixture thereof.
According to claim 2,
Wherein the organic solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane, composition.
According to claim 1,
The composition is to inhibit the expression of Atrogin-1 and MuRF-1 (Muscle RING-finger protein-1) causing muscular atrophy, the composition.
According to claim 1,
Wherein the composition inhibits the expression of Myostatin, which inhibits muscle differentiation.
According to claim 1,
The muscle disease is at least one disease selected from the group consisting of atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscle stiffness, myasthenia, cachexia and sarcopenia. which is, the composition.
A pharmaceutical composition for the prevention or treatment of muscle diseases, comprising copper leaf extract as an active ingredient.
A composition for strengthening muscles comprising copper bamboo extract as an active ingredient.
A composition for stimulating muscle differentiation comprising an extract of copper beetle as an active ingredient.
A composition for enhancing athletic performance comprising copper bamboo extract as an active ingredient.
According to claim 10,
The exercise capacity enhancement is to prevent or improve one or more symptoms selected from the group consisting of degenerative diseases, mitochondrial abnormalities, hypostamina, impotence, lethargy, muscle wasting and depression, composition.

Images